Cerenome Launches CNSide® CSF Molecular Profile Tests

(Nasdaq: CNSY) (“Cerenome” or the “Company ”), today announced the commercial launch of two new cerebrospinal fluid (CSF)-based molecular profiling tests, available to health care professionals in the ...
ascopubs.org

Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children ...

Clinical Impact of the Cell-of-Origin Classification and the MYC/BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade ...
Medical Xpress

Another angle on Alzheimer's: CSF, proteomics, and metabolic enzymes

Currently there are no objective, easily assessed diagnostic markers for Alzheimer's disease, and no good therapeutic options. Taking an agnostic approach, proteomics expert Hanno Steen, Ph.D., and ...
financialcontent

New Peer-Reviewed Study Demonstrates Amprion's Seed Amplification Assay Can Differentiate Multiple System Atrophy from Parkinson's Disease Using Skin Biopsy Samples

According to the study, Amprion's α-synuclein skin SAA successfully differentiated specimens from patients with MSA versus neuronal synuclein disease (NSD) while demonstrating strong agreement with ...